Knight Therapeutics Inc.

TSX:GUD.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$11.56 +0.75%

+$0.07 today

Market cap
$1.14B
Beta
0.07
P/E (TTM)
164.6
EPS (TTM)
$0.06
52W Low $5.66High $9.59

Volume 0.04M

Average 0.10M

GUD.TO EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Knight Therapeutics Inc.TSX: GUD.TO

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA growth accelerates

Q1 FY2026 EBITDA of CA$26.77M rose 106.9% year over year, ahead of the -6.0% change in trailing-twelve-month EBITDA. Sequentially, it rose 25.7% from the prior quarter. Over 3 fiscal years it compounded at +29.1% a year.

Context

  • EBITDA amounted to 12.1% of revenue in FY2025, down 5.3 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 7 analysts of CA$97.41M (+79.2%) for the fiscal year ending Dec 2026, a step up from the -15.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$26.77M+25.7% QoQ
Last fiscal yearDec 2025
CA$54.37M-15.6% YoY
LTMMar 2026
CA$65.18M-6.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+106.9%+1784.9%+1678.1 pp
1 year-15.6%+79.2%+94.7 pp
3-year CAGR+29.1%+39.8%+10.7 pp
5-year CAGR+26.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

CAD · from the income statement

Latest · FY2025
54.37M CAD
Year-over-year change
-15.6%
4-year CAGR
+6.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How GUD.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -6.0% is the 6th highest of 8, against a peer median of +86.8%.
  • EBITDA amounts to 12.8% of revenue for GUD.TO, versus a peer median of 20.3%.
GUD.TO Competitors
EBITDA for GUD.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$65.18M CAD-6.0%+29.1%12.8%
TSND.TOTerrAscend Corp.LTM Mar 2026$60.46M USD+510.4%—23.1%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$25.12M USD+96.0%+26.0%49.3%
VHI.TOVitalhub Corp.LTM Mar 2026CA$24.15M CAD+96.3%+64.2%20.3%
KSI.TOKneat.com, Inc.LTM Mar 2026CA$12.62M CAD-1.2%—19.0%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$9.82M CAD-80.9%—3.1%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026-CA$40.84M CAD-681.4%—14.9%
WEED.TOCanopy Growth CorporationLTM Mar 2026-CA$63.48M CAD+86.8%—20.4%
Peer median (excluding GUD.TO) —+86.8%+45.1%20.3%

Competitors are the stored peer set for GUD.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue243.48M293.56M328.2M371.3M450.09M
Cost of Revenue128.07M155.5M175.55M196.9M299.35M
Gross Profit115.41M138.06M152.65M174.41M150.74M
Gross Margin47.4%47.0%46.5%47.0%33.5%
Research & Development12.69M14.76M17.55M23.3M28.98M
Selling, General & Admin74.38M88.62M83.69M99.35M123.96M
Operating Expenses128.24M155.12M155.54M167.01M152.94M
Depreciation & Amortization47.92M62.62M50.4M53.11M56.57M
EBITDA42.59M25.26M40.9M64.38M54.37M
EBITDA Margin17.5%8.6%12.5%17.3%12.1%
Operating Income(5.32M)(2.4M)(2.89M)7.4M(2.2M)
Operating Margin-2.2%-0.8%-0.9%2.0%-0.5%
Interest Income7.38M10.63M12.58M10.41M6.21M
Interest Expense3.62M6.6M12.49M9.22M10.42M
Other Income / Expenses19.52M(2.92M)(19.1M)(5.35M)(4.5M)
Income Before Tax6.69M(43.96M)(21.99M)2.05M(6.7M)
Pre-Tax Margin2.7%-15.0%-6.7%0.6%-1.5%
Income Tax Expense(8.99M)(14.07M)(5.15M)(2.28M)(1.33M)
Net Income15.68M(29.89M)(16.84M)4.33M(5.37M)
Net Margin6.4%-10.2%-5.1%1.2%-1.2%
EPS (Basic)0.13(0.26)(0.16)0.04(0.05)
EPS (Diluted)0.13(0.26)(0.16)0.04(0.05)
Weighted Avg Shares124.48M114.89M107.47M101.04M99.57M
Weighted Avg Shares (Diluted)124.52M114.89M107.47M101.44M99.57M

Knight Therapeutics Inc.

TSX:GUD.TO

Intrinsic Alpha fair value

Locked

Current Price

$11.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.